5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?
about
Decitabine: a review of its use in older patients with acute myeloid leukaemia.Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesDemethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.The silence of the genes: epigenetic disturbances in haematopoietic malignancies.Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implicationsInduction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Decitabine and its role in the treatment of hematopoietic malignancies.The use of hypomethylating agents in the treatment of hematologic malignancies.HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceEarly epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Pharmacotherapy of myelodysplastic syndromes.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialEpigenetic regulation in myelodysplastic syndromes: implications for therapy.Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation.Cancer testis antigen and immunotherapy.A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.Cardiomyocyte marker expression in a human lymphocyte cell line using mouse cardiomyocyte extract.p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.Epigenetically regulated tumor-associated antigens in melanoma
P2860
Q33407030-A9F4874E-30A9-4B19-B52A-E3D025791226Q33679140-30A72FA5-9121-4C13-9885-D664277B9FCFQ33957165-229EB86B-7258-4B13-9275-A93D8BABFFDCQ33980682-5BFE4F51-0BDC-4CD1-812D-CA2C6902DA0BQ35178504-B47F25C0-F31E-416F-946B-D19023E433CDQ35968482-7CB201DA-A499-4C1B-87F6-A4C75B6683E4Q36056904-B9DB1D70-ADA9-4561-BC52-BD204CBAE070Q36066276-10F5575D-67CC-4F84-81CC-C5B777C649A6Q36287972-60843D7C-F418-43C2-80D1-B4FED85EA1CFQ36445926-A347047D-95E2-4E09-954C-01E9BBECAD13Q36801625-A4743FD8-E9C5-4DE4-83A8-6352948FE09CQ36911488-87CE3AAD-4935-43E4-92F4-038CBFFD3563Q36929658-13F16337-5EEE-45BE-95CF-F5E5CDF03274Q37287152-086C004F-DE9C-4293-A270-11107B5C0488Q37372837-E1D39188-03CF-4701-A84D-8377FF03C499Q37737327-20A00EDE-1553-4259-92D8-2CDEC26AAAD3Q37756975-2F10D255-A3E9-4A78-A297-357D22E3D347Q37849976-32319F46-5E1C-43B4-A7FB-CB1DC9EAA102Q37850456-76ACE565-A9E3-4926-96B7-7623268881FDQ38660984-F7E3132E-EBF6-4911-9C85-3A83036C080BQ38912232-499F21C8-9991-48B2-B2DE-D9704E613EF8Q39181769-6A4F0C36-D771-4A6D-B0B6-CD2DA5C07B93Q39547167-BBF7A77E-5256-45D0-AA73-3183F5DCCAC7Q39916396-985D10B8-89A6-4BC5-BECD-FB5051314134Q40511605-B86CEBDE-D840-42FB-8E11-967C30ECD7A7Q43283507-EB116A33-C621-46F5-9367-5D9D0F9096E2Q46052631-AB85E47C-F2E6-448B-A6E3-66751052BACEQ46839402-553C0688-F4A0-46B3-A841-948C4956392DQ53528762-89DD3FF2-2BE9-4733-9CA4-9128697B8E38Q57570339-634B187A-8A55-4E72-B48A-0E06527C02B3
P2860
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
5-Aza-2'-deoxycytidine (decita ...... echanism therapeutic approach?
@en
type
label
5-Aza-2'-deoxycytidine (decita ...... echanism therapeutic approach?
@en
prefLabel
5-Aza-2'-deoxycytidine (decita ...... echanism therapeutic approach?
@en
P2093
P50
P1433
P1476
5-Aza-2'-deoxycytidine (decita ...... echanism therapeutic approach?
@en
P2093
Antonio Pinto
Francesca Colizzi
Luca Sigalotti
Maresa Altomonte
Massimo Degan
Maurizio Rupolo
P304
4644-6; discussion 4645-6
P356
10.1182/BLOOD-2002-11-3458
P407
P577
2003-06-01T00:00:00Z